WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan. 26, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio’s pipeline.
Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio’s innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.
This partnership reflects HanchorBio’s strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialization. By leveraging WuXi Biologics’ proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.
WuXi Biologics brings extensive experience in complex modalities, including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, there are 945 projects on WuXi Biologics’ integrated platform, with approximately 60% are bi- and multi-specific antibodies, ADCs and fusion proteins, underscoring its track record in enabling accelerated development and manufacturing of advanced therapeutic modalities. Its proprietary technology platforms, such as WuXia™ TrueSite – targeted integration (TI)-based CHO cell line platform, and WuXiHighTM – high-throughput formulation development platform, are designed to enhance speed, quality, and scalability.
For HanchorBio, the collaboration supports continued expansion of its proprietary FBDB™ technology platform, which enables the rational design of multi-functional fusion proteins intended to modulate both innate and adaptive immunity. The partnership represents a significant step in aligning discovery innovation with industrial-scale and globally compliant execution as HanchorBio advances its oncology and autoimmune pipelines toward global clinical development.
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, said: ” We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics’ comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide.”
Dr. Scott Liu, Founder, Chairman, and Chief Executive Officer of HanchorBio, commented: “This partnership with WuXi Biologics strengthens our ability to translate platform-driven innovation into high-quality clinical and commercial assets. As we advance multiple next-generation fusion protein programs, execution speed, manufacturing reliability, and scalability are critical. WuXi Biologics’ proven expertise in complex biologics and global development makes them a strong strategic partner as we build a differentiated, multi-asset immunotherapy pipeline.”
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
[email protected]
Business
[email protected]
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, aiming to activate both innate and adaptive immune pathways to overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies. For more information, please visit:
Contacts
[email protected]
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
HONG KONG, Jan. 28, 2026 /PRNewswire/ — The Hon. Prime Minister of the Republic of Vanuatu – Jotham Napat Nauka, led a senior government delegation to Hong Kong and successfully convene the event “Future and Development of Vanuatu–Hong Kong Relationship for 2026 and beyond: Press conference of the Hon. Prime Minister of the Republic of Vanuatu’s visit to Hong Kong” during which he delivered a keynote address on the future trajectory of Vanuatu–Hong Kong relations.
The Hon. Prime Minister Napat stated that the visit marks the entry of Vanuatu–Hong Kong relations into a new phase characterized by strengthened political mutual trust, deeper institutional engagement, upgraded financial cooperation, and comprehensive connectivity with capital markets.
During the visit, the Hon. Prime Minister held pragmatic and productive meetings with Leaders and Senior Officials of the Government of the Hong Kong S.A.R on issues of common interest as it highlights that bilateral trade between Hong Kong and Vanuatu continues to grow, adding that the prospects for co-operation between the two places are broad and promising.
The Hon. Prime Minister met with the Hon. John KC LEE Chief Executive, and the two leaders exchanged views on issues of mutual interest reaching a high degree of consensus on the future direction of bilateral relations.
Both sides agreed that, against the backdrop of profound adjustments in the international landscape and the continued deepening of regional cooperation, Vanuatu–Hong Kong relations possess broad strategic potential. They emphasized the need to elevate the level of cooperation, expand its scope, and improve cooperation mechanisms, advancing bilateral relations from project-based collaboration toward institutionalized, structural, and long-term partnerships.
Both sides agree to establish more stable, regularized, and mechanism-based frameworks that set the base for communication and coordination, and enhance dialogue across areas of mutual interest: including regional affairs, development agendas, international organizations, economic governance, financial regulation, and institutional development.
Both sides agree to actively advance the establishment of principles for financial parity and mutual recognition of relevant licenses and progressively build a medium- to long-term cooperation framework encompassing both traditional finance and emerging digital finance.
Both sides also agree to strengthen bilateral synergies within regional financial systems and further consolidate political trust and policy alignment. Through enhanced intergovernmental strategic communication and policy coordination, the two sides aim to foster a more transparent, predictable, and sustainable institutional environment for enterprises, financial institutions, and market participants to engage in cross-border cooperation.
The Hon. Prime Minister Napat further noted that Hong Kong, as an international financial center and a highly open economy, possesses mature experience and global influence in governance frameworks, financial regulation, capital market development, and alignment with international standards.
The Hon. Prime Minister further mentioned that Vanuatu, as an important island nation in the South Pacific, offers strategic geographic advantages, institutional flexibility, and strong regional connectivity potential. With complementary strengths and highly aligned development priorities, the two sides are well positioned to build a comprehensive partnership encompassing political trust, economic cooperation, financial coordination, and institutional innovation, jointly contributing to regional stability and sustainable development.
In the areas of trade, investment, and people-to-people exchanges, both sides conducted systematic, structured, and forward-looking discussions on trade and investment facilitation, industrial cooperation, tourism collaboration, business exchanges, talent development, and two-way mobility, and reached broad consensus on further enhancing both the quality and scale of bilateral economic and trade cooperation.
Both sides expressed strong support for more Hong Kong and international enterprises to leverage Hong Kong as a platform hub to engage in practical cooperation with Vanuatu across priority development sectors including infrastructure, green energy, the digital economy, financial services, shipping and logistics, the marine economy, modern agriculture, and sustainable tourism.
Both sides agreed that continued consultations and implementation efforts are essential and will work to advance bilateral cooperation from traditional project-based engagement toward industrial chain collaboration, capital alignment, and institutional co-development. In terms of people-to-people exchanges, both sides will continue to optimize mechanisms for the mobility of business, investment, and professional services personnel, support enhanced exchanges among universities, research institutions, financial institutions, and professional service organizations, and promote talent development, capacity building, and the sharing of institutional experience, thereby further strengthening the social and industrial foundations of bilateral relations.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Future and Development of Vanuatu-Hong Kong Relationship for 2026 and beyond: Conference held by the Hon. Prime Minister of Vanuatu on his successful visit to Hong Kong
link
